碳酸鈣/矽酸鈣複合微粒製備及性質探討

本研究使用化學沉降法製備碳酸鈣/矽酸鈣複合微粒，並探討其基本物化性值。碳酸鈣與矽酸鈣皆具有優良的骨修復能力，已被應用於硬骨組織修復工程許久，碳酸鈣具降解性、矽酸鈣則具有藥物吸附特性，由於CaCO3使用吸附法附載藥物能力差，以及CaSiO3形態難以製備成球形，因此希望經由製程改善製備出具不同物化性值之CaCO3/CaSiO3複合微粒製備出具降解性及藥物吸附能力之微粒。製程變因為矽及二氧化碳效應以及2種鈣（氯化鈣與硝酸鈣）來源，共6組條件，其代號分別為：CaCl2-0S、CaCl2-3S、CaCl2-3S No CO2、Ca(NO3)2-0S Ca(NO3)2-3S以及Ca(NO3)2-3S No CO2。於掃描式電子顯微鏡觀察結構以及能量散射光譜儀元素分析，證實使用化學沉降法配合二氧化碳反應能成功製備出直徑約7–15 μm的球形碳酸鈣/矽酸鈣複合微粒(CaCl2-3S、Ca(NO3)2-3S)，於模擬人體體液浸泡實驗後的微粒表面生長氫氧基磷灰石，因此推測微粒將具有生物活性，且於浸泡實驗結果亦得知其微粒具優良降解性；於傅立葉轉換光譜儀以及X光繞射儀分析得知微粒具有方解石以及球霰石晶相，其中Ca(NO3)2-3S經模擬人體體液浸泡後亦能維持球霰石晶相。將微粒製成細胞培養萃取液與類人骨肉瘤細胞株進行培養，結果皆具有促進細胞增生之能力，其萃取液濃度愈高其促進性愈高；使用慶大黴素抗生素以及亞甲基藍水合物作為藥物吸附能力測試藥物得知，碳酸鈣微粒中若含矽成份，則能成功提升其微粒之藥物吸附能力，以及具有藥物釋放能力。實驗條件為0S之組別，對亞甲基藍吸附量為2.19% 3.65，添加矽成份後(3S)其藥物吸附量則提升至27.09% 2.78；實驗條件為0S之組別，對慶大霉素抗生素藥物吸附量為0.22% 0.01，添加矽成份後(3S)其藥物吸附量則提升至7.22% 1.33。總結以上實驗結果證實，此研究所製備出的碳酸鈣/矽酸鈣複合微粒，具有相當潛力可應用於藥物制放以及骨組織工程。

關鍵字

碳酸鈣；矽酸鈣；複合微粒；藥物載體

並列摘要

Bioceramic microspheres for bone regeneration applications should have good properties of bioactivity, biodegradability, and controlled drug-release ability. Calcium carbonate has high degradable feature and calcium silicate exhibits good bioactivity and controlled drug-release ability. However calcium carbonate has not good drug loading capacity in incorporation method, and calcium silicate is difficult to prepares for sphere shape. Therefore, calcium carbonate/calcium silicate composite microspheres (Ca/Si sphere) with desirable properties were prepared using the chemical precipitation methods. The effect of silicate ions and carbon dioxide and two kinds of calcium ions on the properties of the composite microspheres was investigated with scanning electron microscopy (SEM), energy dispersive spectroscopic (EDS), X-ray diffraction (XRD), and fourier transform infrared spectroscopy (FTIR). The biodegradability and bioactivity were examined by immersing in simulated body fluid (SBF). The cell proliferation and differtiation assays were performed by extraction method with MG63 cell line. Additionally, gentamicine (Gen) and methylene blue (MB) were used as model for evaluating the feasibility of Ca/Si spheres as a drug-delivery system. The SEM images illustrated monodispersed microspheres with size of about 7–15 μm. XRD and FTIR demonstrated that the structure consisted of calcite and vaterite phases. After immersion in SBF, the Ca/Si spheres retained vaterite phase. While silicate ions were incorporated into microspheres, the loading capacity of Gen and MB were remarkably enhanced from original 2.19% 3.65 to 27.09% 2.78 and original 0.22% 0.01 to 7.22% 1.33, respectively. The viability of MG63 cells seeded with Ca/Si spheres revealed good cell proliferation. It is concluded that the developed Ca/Si microspheres might have potential to be used as the drug carriers and for bone repair applications.

並列關鍵字

Calium carbonate ； calcium silicate ； microsphere ； drug carrier.

參考文獻

[4] Hulbert SF, Hench LL, Forbers D, Bowman LS. History of bioceramics. Ceram. Int. 1982:8;131–140.

[5] Hench LL, Polak JM. Third-generation biomedical materials. Science. 2002;295:1014–1017.

[6] Hench LL. Bioceramics. J. Am. Ceram. Soc. 1998;81:1705–1728.

[7] Hench LL, Splinter RJ, Allen WC, Greenlee TK. Bonding mechanisms at the interface of ceramic prosthetic materials. J. Biomed. Mater. Res. 1971;5:117–141

[8] Matsuda T, Davies JE. The in vitro response of osteoblasts to bioactive glass. Biomaterials. 1987;8:275–284.

國際替代計量

碳酸鈣/矽酸鈣複合微粒製備及性質探討

全文下載

主題瀏覽